Grimes & Company Inc. grew its stake in shares of The Clorox Company (NYSE:CLX - Free Report) by 16.2% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 68,879 shares of the company's stock after purchasing an additional 9,615 shares during the quarter. Grimes & Company Inc. owned about 0.06% of Clorox worth $8,270,000 at the end of the most recent quarter.
Several other institutional investors have also recently made changes to their positions in CLX. Vanguard Group Inc. increased its holdings in shares of Clorox by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 15,573,076 shares of the company's stock worth $2,293,135,000 after acquiring an additional 65,924 shares during the last quarter. Northern Trust Corp increased its holdings in shares of Clorox by 2.3% during the 1st quarter. Northern Trust Corp now owns 1,528,920 shares of the company's stock worth $225,133,000 after acquiring an additional 34,655 shares during the last quarter. Invesco Ltd. increased its holdings in shares of Clorox by 7.4% during the 1st quarter. Invesco Ltd. now owns 1,361,710 shares of the company's stock worth $200,512,000 after acquiring an additional 94,371 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Clorox by 3.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,157,257 shares of the company's stock worth $170,406,000 after acquiring an additional 41,485 shares during the last quarter. Finally, Hsbc Holdings PLC increased its holdings in shares of Clorox by 118.8% during the 1st quarter. Hsbc Holdings PLC now owns 1,085,661 shares of the company's stock worth $159,699,000 after acquiring an additional 589,544 shares during the last quarter. Institutional investors and hedge funds own 78.53% of the company's stock.
Clorox Stock Performance
NYSE:CLX opened at $123.30 on Monday. The stock has a fifty day moving average price of $122.81 and a 200-day moving average price of $129.41. The company has a market cap of $15.08 billion, a price-to-earnings ratio of 18.91, a PEG ratio of 1.00 and a beta of 0.52. The company has a debt-to-equity ratio of 5.15, a quick ratio of 0.57 and a current ratio of 0.84. The Clorox Company has a fifty-two week low of $116.53 and a fifty-two week high of $171.37.
Clorox (NYSE:CLX - Get Free Report) last released its earnings results on Thursday, July 31st. The company reported $2.87 earnings per share for the quarter, beating analysts' consensus estimates of $2.24 by $0.63. The firm had revenue of $1.99 billion during the quarter, compared to the consensus estimate of $1.94 billion. Clorox had a return on equity of 377.86% and a net margin of 11.40%.The company's revenue was up 4.5% compared to the same quarter last year. During the same period in the prior year, the company posted $1.82 EPS. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. As a group, equities analysts anticipate that The Clorox Company will post 7.15 EPS for the current fiscal year.
Clorox Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, November 6th. Stockholders of record on Wednesday, October 22nd will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 4.0%. The ex-dividend date is Wednesday, October 22nd. Clorox's dividend payout ratio is presently 76.07%.
Insider Buying and Selling at Clorox
In related news, COO Eric H. Reynolds sold 15,041 shares of the company's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the completion of the sale, the chief operating officer directly owned 54,221 shares in the company, valued at $6,711,475.38. This represents a 21.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.57% of the stock is currently owned by corporate insiders.
Analyst Ratings Changes
A number of research analysts recently weighed in on CLX shares. TD Cowen decreased their target price on Clorox from $120.00 to $117.00 and set a "hold" rating on the stock in a report on Wednesday, October 1st. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Clorox in a report on Saturday, September 27th. UBS Group decreased their price objective on Clorox from $150.00 to $134.00 and set a "neutral" rating on the stock in a report on Thursday, July 17th. Wells Fargo & Company decreased their price objective on Clorox from $130.00 to $125.00 and set an "equal weight" rating on the stock in a report on Thursday, September 25th. Finally, Morgan Stanley decreased their price objective on Clorox from $150.00 to $137.00 and set an "equal weight" rating on the stock in a report on Friday, August 1st. One research analyst has rated the stock with a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Reduce" and a consensus target price of $134.08.
Read Our Latest Stock Report on CLX
Clorox Profile
(
Free Report)
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Clorox, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clorox wasn't on the list.
While Clorox currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report